later confirmation study way scientists hoffmann la roche described new findings antiamyloid drug gantenerumab large trial monoclonal antibody canceled december 2014 failed measurable effects researchers reanalyzed data considering patients early rapidly progressing disease found gantenerumab reduced beta amyloid pet scans group reduced levels tau protein builds inside neurons alzheimer advances forming tangles fritz normal cell function reports underscore importance early intervention certain point late stem amyloid tide trials probing antiamyloid drugs powerful preventively called a4 study joint effort national institutes health eli lilly nonprofit organizations testing solanezumab patients not display memory deficits increased levels beta amyloid pet scans investigations exploring